Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia.
IPSS
alpha‐1 blocker
chronic prostatic inflammation
dihydrotestosterone
dutasteride
high endothelial venule‐like vessel
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
26
05
2024
accepted:
03
10
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
23
10
2024
Statut:
aheadofprint
Résumé
α-1 blockers and dutasteride are widely used as agents to treat benign prostatic hyperplasia (BPH); the impact of these drugs on prostatic inflammation is still unclear. Herein, we investigated the impact of α-1 blockers and dutasteride treatment of BPH in terms of the degree of prostatic inflammation. Tissue specimens were obtained from 143 BPH patients who were administered α-1 blockers up until their operation. Thirty-three of the patients had also been treated with dutasteride before the procedure. The degree of prostatic inflammation was quantified histologically by the ratio of high endothelial venule (HEV)-like vessels. We divided this retrospective cohort into α-1 blocker monotherapy and combination therapy (α-1 blockers + dutasteride) groups and evaluated clinical parameters of the two groups in relation to the degree of chronic prostatic inflammation. At the same time, we assessed factors exacerbating chronic prostatic inflammation. Comparison of the monotherapy and combination therapy groups showed no significant differences in the parameters of the urodynamic study or degree of chronic prostatic inflammation, whereas the IPSS total score, voiding subscore, nocturia, intermittency, weak stream, and straining were significantly lower in the combination than the monotherapy group. The duration of α-1 blockers administration was not correlated with the ratio of HEV-like vessels, while that of dutasteride was strongly correlated (correlation coefficient = 0.595; p < 0.001). Multiple regression analysis demonstrated that the duration of dutasteride administration was a key factor exacerbating the degree of chronic prostatic inflammation. The present study showed that despite their ameliorating effect on prostatic hyperplasia, dutasteride contributed significantly to chronic prostatic inflammation.
Sections du résumé
BACKGROUND
BACKGROUND
α-1 blockers and dutasteride are widely used as agents to treat benign prostatic hyperplasia (BPH); the impact of these drugs on prostatic inflammation is still unclear. Herein, we investigated the impact of α-1 blockers and dutasteride treatment of BPH in terms of the degree of prostatic inflammation.
MATERIALS AND METHODS
METHODS
Tissue specimens were obtained from 143 BPH patients who were administered α-1 blockers up until their operation. Thirty-three of the patients had also been treated with dutasteride before the procedure. The degree of prostatic inflammation was quantified histologically by the ratio of high endothelial venule (HEV)-like vessels. We divided this retrospective cohort into α-1 blocker monotherapy and combination therapy (α-1 blockers + dutasteride) groups and evaluated clinical parameters of the two groups in relation to the degree of chronic prostatic inflammation. At the same time, we assessed factors exacerbating chronic prostatic inflammation.
RESULTS
RESULTS
Comparison of the monotherapy and combination therapy groups showed no significant differences in the parameters of the urodynamic study or degree of chronic prostatic inflammation, whereas the IPSS total score, voiding subscore, nocturia, intermittency, weak stream, and straining were significantly lower in the combination than the monotherapy group. The duration of α-1 blockers administration was not correlated with the ratio of HEV-like vessels, while that of dutasteride was strongly correlated (correlation coefficient = 0.595; p < 0.001). Multiple regression analysis demonstrated that the duration of dutasteride administration was a key factor exacerbating the degree of chronic prostatic inflammation.
CONCLUSIONS
CONCLUSIONS
The present study showed that despite their ameliorating effect on prostatic hyperplasia, dutasteride contributed significantly to chronic prostatic inflammation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association.
Références
Carson C 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61:2–7.
Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379–1384.
Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009;69:1774–1780.
Inamura S, Shinagawa T, Hoshino H, Sakai Y, Imamura Y, Yokoyama O, et al. Appearance of high endothelial venule‐like vessels in benign prostatic hyperplasia is associated with lower urinary tract symptoms. Prostate. 2017;77:794–802.
Funahashi Y, Takahashi R, Mizoguchi S, Suzuki T, Takaoka E, Ni J, et al. Bladder overactivity and afferent hyperexcitability induced by prostate‐to‐bladder cross‐sensitization in rats with prostatic inflammation. J Physiol. 2019;597:2063–2078.
Nickel JC, Roehrborn C, Montorsi F, Wilson TH, Rittmaster RS. Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. J Urol. 2011;186:1313–1318.
Nickel JC, O'Leary MP, Lepor H, Caramelli KE, Thomas H, Hill LA, et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. J Urol. 2011;186:125–131.
Xu J, Itoh Y, Hayashi H, Takii T, Miyazawa K, Onozaki K. Dihydrotestosterone inhibits interleukin‐1α or tumor necrosis factor α‐induced proinflammatory cytokine production via androgen receptor‐dependent inhibition of nuclear factor‐κB activation in rheumatoid fibroblast‐like synovial cell line. Biol Pharm Bull. 2011;34:1724–1730.
Barnes PJ, Karin M. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:336–1071.
Han Y, Runge MS, Brasier AR. Angiotensin II induces Interleukin‐6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor‐κB transcription factors. Circ Res. 1999;84:695–703.
Xu S, Zhi H, Hou X, Jiang B. Angiotensin II modulates interleukin‐1β‐induced inflammatory gene expression in vascular smooth muscle cells via interfering with ERK‐NF‐κB crosstalk. Biochem Biophys Res Commun. 2011;410:543–548.
Ito H, Wang D, Zha X, Inamura S, Seki M, Taga M, et al. Castration increases PGE(2) release from the bladder epithelium in male rats. Life Sci. 2018;193:252–256.
Sakai Y, Kobayashi M. Lymphocyte ‘homing’ and chronic inflammation. Pathol Int. 2015;65:344–354.
Stoolman LM, Yednock TA, Rosen SD. Homing receptors on human and rodent lymphocytes—evidence for a conserved carbohydrate‐binding specificity. Blood. 1987;70:1842–1850.
Matsukawa Y, Gotoh M, Kato M, Funahashi Y, Narita M, Mitsui K. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1‐year outcomes from a prospective urodynamic study. Int J Urol. 2014;21:826–830.
Yeh J‐C, Hiraoka N, Petryniak B, Nakayama J, Ellies LG, Rabuka D, et al. Novel sulfated lymphocyte homing receptors and their control by a Core1 extension β1,3‐N‐acetylglucosaminyltransferase. Cell. 2001;105:957–969.
Streeter PR, Rouse BT, Butcher EC. Immunohistologic and functional characterization of a vascular address in involved in lymphocyte homing into peripheral lymph nodes. J Cell Biol. 1988;107:1853–1862.
Uchimura K, Rosen SD. Sulfated L‐selectin ligands as a therapeutic target in chronic inflammation. Trends Immunol. 2006;27:559–565.
Taga M, Hoshino H, Low S, Imamura Y, Ito H, Yokoyama O, et al. A potential role for 6‐sulfo sialyl Lewis X in metastasis of bladder urothelial carcinoma. Urol Oncol. 2015;33:e1–e9.
Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol. 2004;92:237–253.
Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P, et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol. 2012;214:31–43.
Suzuki Y, Ruiz‐Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35:881–900.
Guo F, Weih D, Meier E, Weih F. Constitutive alternative NF‐kappaB signaling promotes marginal zone B‐cell development but disrupts the marginal sinus and induces HEV‐like structures in the spleen. Blood. 2007;110:2381–2389.
Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, et al. The effect of 5alpha‐reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92:1659–1665.
Funahashi Y, Majima T, Matsukawa Y, Yamamoto T, Yoshida M, Gotoh M. Intraprostatic reflux of urine induces inflammation in a rat. Prostate. 2017;77:164–172.
Shimizu S, Shimizu T, Tsounapi P, Higashi Y, Martin DT, Nakamura K, et al. Effect of silodosin, an Alpha1A‐adrenoceptor antagonist, on ventral prostatic hyperplasia in the spontaneously hypertensive rat. PLoS One. 2015;10:e0133798.
Zaitsu M, Tonooka A, Mikami K, Hattori M, Takeshima Y, Uekusa T, et al. A dual 5α‐reductase inhibitor dutasteride caused reductions in vascular density and area in benign prostatic hyperplasia. ISRN Urol. 2013;2013:1–8.
Kobayashi H, Zha X, Nagase K, Inamura S, Taga M, Aoki Y, et al. Phosphodiesterase 5 inhibitor suppresses prostate weight increase in type 2 diabetic rats. Life Sci. 2022;298:120504.
Nomiya M, Sagawa K, Yazaki J, Takahashi N, Kushida N, Haga N, et al. Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis‐induced chronic bladder ischemia. Neurourol Urodyn. 2012;31:185–189.
Di Silverio F, Bosman C, Salvatori M, Albanesi L, Pannunzi LP, Ciccariello M, et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:72–79.